Cost-Effectiveness Evaluation of Add-on Empagliflozin in Patients With Heart Failure and a Reduced Ejection Fraction From the Healthcare System's Perspective in the Asia-Pacific Region

Background: EMPEROR-Reduced trial provides promising evidence on the efficacy of empagliflozin adding to the standard treatment in patients with heart failure and reduced ejection fraction (HFrEF). This study aimed to investigate the cost-effectiveness of add-on empagliflozin vs. standard therapy al...

Descripción completa

Detalles Bibliográficos
Autores principales: Liao, Chia-Te, Yang, Chun-Ting, Kuo, Fang-Hsiu, Lee, Mei-Chuan, Chang, Wei-Ting, Tang, Hsin-Ju, Hua, Yi-Ming, Chang, Hung-Yu, Chen, Zhih-Cherng, Strong, Carol, Ou, Huang-Tz, Toh, Han Siong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Cardiovascular Medicine
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8586201/
https://www.ncbi.nlm.nih.gov/pubmed/34778407
http://dx.doi.org/10.3389/fcvm.2021.750381

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8586201/
https://www.ncbi.nlm.nih.gov/pubmed/34778407
http://dx.doi.org/10.3389/fcvm.2021.750381

Ejemplares similares